Disease-free survival favors the groups of carcinoma patients with wild-type p53 and high ZDHHC1 expression while the group with mutated p53 and lower ZDHHC1 had the shortest disease-free survival (Fig. 1C; Fig. S1B). Here, TP53 is linked to carcinoma.